Pulse Biosciences (PLSE) Common Equity (2015 - 2025)

Pulse Biosciences has reported Common Equity for 11 years, with the latest figure at $80.7 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 29.78% year-over-year to $80.7 million; the trailing twelve-month figure through Dec 2025 stood at $80.7 million (down 29.78% YoY), and the FY2025 full-year result was $80.7 million, down 29.78% from the prior year.
• Common Equity for Q4 2025 stood at $80.7 million, down from $92.7 million in the prior quarter.
• The five-year high for Common Equity was $118.5 million in Q1 2025, with the low at -$10.7 million in Q1 2023.
• Average Common Equity over 5 years is $51.0 million, with a median of $45.9 million recorded in 2021.
• Peak annual rise in Common Equity reached 2073.31% in 2023, while the deepest fall reached 151.29% in 2023.
• Tracing PLSE's Common Equity over 5 years: stood at $44.4 million in 2021, then slumped by 105.07% to -$2.2 million in 2022, then jumped by 2073.31% to $44.4 million in 2023, then jumped by 158.93% to $114.9 million in 2024, then dropped by 29.78% to $80.7 million in 2025.
• The last three Common Equity figures came in at $80.7 million (Q4 2025), $92.7 million (Q3 2025), and $104.5 million (Q2 2025), per Business Quant data.

Peer Comparison